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were enrolled. Only 4.5% were not assessable and 659 (86.5%)
were able to answer the SATMED-Q. The oretical 6 factor solu-
tion explained 82.8% of the available variance; it was well
deﬁned, and all communalities were above 0.76. A strong cor-
relation between Effectiveness and Impact on Daily Activities 
(r = 0.525) was found. Dimensional Cronbach’s á ranged
between 0.857 and 0.936. The one-dimensional ICC was 0.893
(0.890–0.905, 95% CI) and Guttman two-half index was 0.935.
No signiﬁcant correlation was found between age and Treatment
Satisfaction (r = 0.055), Anxiety (r = −0.17), and Depression 
(r = 0.075). Neither between educational level and Anxiety (r =
−0.038), but educational level showed to be related with Depres-
sion (r = −0.204; p < 0.001) and Treatment Satisfaction (r =
0.169; p < 0.001). Treatment Satisfaction dimension levels inter-
act signiﬁcantly with Depression (p < 0.001) and Anxiety (p <
0.011) severity levels. CONCLUSIONS: The psychometric prop-
erties of the SATMED-Q are good in this speciﬁc population.
Signiﬁcant differences in Treatment Satisfaction are found
depending on the Anxiety and Depression level.
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OBJECTIVES: Multiple Sclerosis (MS) is a chronic neurological
disease affecting the central nervous system with a prevalence
rate of 240 per 100,000 in Canada. The prevalence of pain in
MS ranges from 10%–80% (70% in a study we previously per-
formed). Sativex® (SAT) is a new cannabis-based drug approved
in Canada for neuropathic pain in patients with MS. Willing-
ness-to-pay (WTP) elicits the extent of subjects’ preference for
their chosen treatment, expressed as the amount they would
hypothetically be willing to pay in insurance premiums in order
to have access to the treatment. METHODS: The WTP instru-
ment had a decision board (DB) and a questionnaire. A DB is a
visual aid to help clinicians present clinical information about
treatment options in a standardized manner. Two treatment
options were presented on the board used in this study, with text
and data describing them obtained from clinical experts and the
literature. The ﬁrst option was a “cocktail” of three medications:
gabapentin, amytriptylin, and acetaminophen (“pills”), while the
comparator was the same “cocktail” but adding SAT (“pills and
oral spray”). The WTP instrument was administered to 500 par-
ticipants from the general Canadian population, using the
bidding game approach. Descriptive statistics were calculated.
RESULTS: The mean age of the study population was 39 ± 13
years, 56% were female. The DB was facilitated in English
(85%) and French (15%). Of the 500 interviews conducted, 253
respondents chose the “pills and oral spray” option. For these
subjects, the mean WTP per month in additional insurance
premium was CAD $8 (range = $0–$200, median = $4). CON-
CLUSION: Assuming only 51% in a general population are
willing to pay additional premiums as reported, the obtained
WTP would be able to fund the drug for all MS patients with
pain (assumed 70%), with a remaining surplus of $3.24/person.
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OBJECTIVES: This study used a stated preference discrete
choice experiment (DCE) to explore the preferences and will-
ingness to pay (WTP) of RR-MS patients in the UK regarding
the beneﬁts of treatments. METHODS: The attributes in the
DCE included the number of future relapses, presence of new
nerve damage, progression in disability level and out of pocket
cost (to estimate WTP for changes in attribute levels). Partici-
pants were asked to indicate their preference for hypothetical
treatment proﬁles that varied attribute levels based on an orthog-
onal fold-over design. The patient sample (n = 194) was recruited
through advertisement with a patient advocacy group. WTP was
estimated using logit analysis. RESULTS: Eighty-three percent of
patients (mean age 44 years, 82% female) had experienced 1 or
more relapses in the last 2 years and 46% required aid with
ambulation. Patients had a mean annual household income of
≤33,000 and monthly MS-related expenditures of approximately
≤50. The estimated monthly WTP for a combined beneﬁt of 
no disability progression, new nerve damage or relapses was
approximately 9 times their current expenditures and 16% of
their mean annual income. The most highly valued treatment
outcome was avoidance of disability progression in the next year.
Segmented analyses indicated that patients not currently experi-
encing a relapse and those with lower self-reported levels of dis-
ability had higher WTP for improvements in the other treatment
beneﬁt attributes. CONCLUSION: RR-MS patients indicated a
differential demand for avoidance of MS related disability pro-
gression, relapses and nerve damage. Patients who were less
severely affected by their RR-MS were willing to pay more to
reduce the burden of their disease. This study underlines the high
value patients place on the avoidance of MS sequelae, particu-
larly disability progression.
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OBJECTIVES: Aim of our study is to analyse the 30 days mor-
tality of patients over 60 with femoral neck fracture according
to comorbidities at admission. METHODS: Data derives from
the database of National Health Insurance Fund Administration
and based on the S7200 code (femoral neck fracture) of Inter-
national Classiﬁcation of Diseases (ICD) tenth revision and the
codes of comorbidities. The retrospective study is based on
patients discharged in 2000 from the institutions providing deﬁn-
itive care after the primary treatment of femoral neck fracture.
Financial data has been controlled with a nationwide institu-
tional questionnaire. We calculated 30 days mortality as a time
between hospital admission and death. Early mortality rates are
presented according to the dominant occurrence most frequently
found comorbidities. RESULTS: Altogether 3783 patients over
60 years met the inclusion criteria. The overall 30 days mortal-
ity was 9%. The mortality of patients with comorbidities was
9.65%, while without comorbidities it was 2.1%. The early mor-
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tality rate was the following in case of the most common comor-
bidities: Mental and behavioural disorders (F00-F99) 16.1%;
Malignant neoplasms (C00-C97) 18.9%; Diabetes mellitus and
other disorders of glucose regulation and pancreatic internal
secretion (E10-E16) 10.4%; Extrapyramidal and movement dis-
orders (G20-G26) 14.3%; Cerebrovascular diseases (I60-I69)
11.8%; Ischaemic heart diseases (I20-I25) 11.3%; Other forms
of heart disease (I30-I52) 28.1%; Hypertensive diseases (I10-I15)
8%; decubitus ulcers (L89) 23%; Atherosclerosis (I70) 14.1%;
Acute upper and lower respiratory infections (J00-J22) 43.9%;
Chronic lower respiratory diseases (J40-J47) 14.3%. CON-
CLUSIONS: The presence of comorbidities increases the chance
for mortality. In order to decrease the risk of mortality, one has
to treat the comorbidities also. The coexistence of several
comorbidities, multiplies the chance of mortality. The mortality
values after femoral neck fractures reveals the necessity of
comorbidities’ treatment emphasizing the importance of postop-
erative interdisciplinary cooperation.
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OBJECTIVES: To study the association between low compliance
with bisphosphonate therapy and the risk of osteoporotic frac-
ture. METHODS: New female users of daily or weekly alen-
dronate or risedronate between 1999 and 2004, aged ≥45 years
or with diagnosed post-menopausal osteoporosis were identiﬁed
from the PHARMO database, including among others linked
drug-dispensing and hospitalization data for over two million
residents of The Netherlands. Patients were followed from their
ﬁrst bisphosphonate dispensing until their ﬁrst hospitalisation
for osteoporotic fracture, death, or end of the study period.
Compliance with bisphosphonates during follow-up was mea-
sured over 90-day intervals using the Medication Possession
Ratio (MPR), deﬁned as the sum of days’ supply of all alen-
dronate and risedronate dispensed to each patient per 90-day
interval. Data were analysed univariately and multivariately
using time-dependent Cox regression analysis. RESULTS: The
study cohort included 8822 new female users of alendronate or
risedronate. During follow-up, 216 osteoporotic fractures
occurred, of which 40 excluded fractures during the ﬁrst 6
months. The percentage of non-compliant patients (MPR <
80%) increased from 34% after 6 months to 60% after 3 years
of follow-up. Non-compliant bisphosphonate use was associated
with a 40% increased risk of fracture (95% CI 4%–90%,
adjusted for age and fracture history) compared to compliant bis-
phosphonate use. This corresponds to a 30% loss of treatment
beneﬁt. Classifying compliance into 5 categories, fracture risk
gradually increased with poorer compliance (p trend < 0.05) to
an 80% risk increase with very low compliance (MPR < 20%),
corresponding to a 45% loss of treatment beneﬁt. CONCLU-
SIONS: The results of this study show a direct link between level
of compliance with oral bisphosphonates and level of fracture
risk. Thus, treatment compliance is vital to obtain maximal bone
protection. To increase compliance, and therefore treatment
beneﬁt, the advent of bisphosphonates with more convenient
dosing regimes is important.
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OBJECTIVES: The purpose of this study was to analyse the 5
year survival rate after medial femoral neck fracture according
to type of fracture (medial or lateral) over 60. METHODS: The
data derives from the ﬁnancial database of the Hungarian
National Health Insurance Fund Administration, based on the
tenth revision of the International Classiﬁcation of Diseases
(ICD) with ICD code S7200 and on the Hungarian Diagnosis
Related Group (DRG) system. The following patients were
included into the study: having social insurance identiﬁcation
number, being discharged in 2000 after primary treatment of
femoral neck fracture. The patients with polytrauma were
excluded from the study. Statistical analysis was carried out with
SPSS 14.0 for Windows. We created Kaplan-Meier survival
curves (at 2170 days) and calculated chi-square values (Mantel-
Cox log rank test). RESULTS: Altogether N = 3783 patients
from the whole country were included into the study (mean age
= 77.97 ± 8.513). 436 patients (mean age = 78.56 ± 8.934) had
lateral while 3347 patients (mean age = 77.89 ± 8.456) had
medial femoral neck fracture. One-way analysis of variance
(ANOVA) showed no signiﬁcant difference in the mean age of
the two groups of patients (F = 2.594, P = 0.126). Overall sur-
vival at 5 years follow up was 29.36% for patients with lateral
and 35.96% for patients with medial femoral neck fracture. Sta-
tistical analysis showed that type of fracture had a highly sig-
niﬁcant effect on mortality (log rank test 14.30, df = 1, p =
0.0002). CONCLUSIONS: We found signiﬁcant difference in
survival of patients depending on the type of femoral neck frac-
ture (medial or lateral). Although survival is inﬂuenced by many
other factors (e.g. co-morbidities, complications, etc.), the type
of fracture is important. We emphasize the role of large admin-
istrative databases in order to analyse “real word” data.
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OBJECTIVES: Recombinant human bone morphogenetic
protein (rhBMP2) is a novel biologic therapy that promotes bone
growth at the fracture site. We compared the cost and cost-effec-
tiveness of rhBMP-2 in open tibia fractures in Germany, France
and UK. METHODS: We developed an economic model to
compare rhBMP-2 + standard of care (soft tissue management
and intramedullary nailing) with standard of care alone. Clini-
cal data was obtained from the BMP-2 Evaluation for Surgery
in Tibial Trauma (BESTT) trial and cost data from the national
tariffs (German-DRG, UK-NHS, French-Social Security tariffs),
reported in 2005 values. Utility weights were assigned to differ-
ent grades (Gustillo I–IIIB) of open tibia fractures and differences
in treatment outcomes were calculated. We performed the analy-
sis from payer’s/health care system’s perspective for a one year
time-horizon. RESULTS: In Germany, use of rhBMP-2 for grade
III open tibia fractures resulted in cost-savings of €4073 per
patient that offsets the upfront cost of rhBMP2 (€2950), repre-
